Hydrogels for Sustained Drug Release with Intraocular Lens Implantation for Cataract Surgery

Shai Garty1,2, Rika Shirakawa1,3, James D. Bryers2, Bubby D. Ratner2, Tueng. T. Shen1,2.

1. Department of Ophthalmology, University of Washington, Seattle, WA, USA
2. Department of Bioengineering, University of Washington, Seattle, WA, USA
3. Department of Ophthalmology, University of Tokyo, Tokyo, Japan.

Statement of Purpose: Cataract is the leading cause of treatable blindness worldwide and the population afflicted by cataract is increasing globally [1]. Post-operative infection is a major concern resulting from suboptimal sterile operating conditions and scarce availability of post-operative medication, leading to bacterial growth and biofilm formation that blocks the vision pathway, causing repeated blindness [2]. We aim to develop a novel drug delivery system that allows sustained sufficient antibiotic level during the post-operative recovery period for cataract surgery. The development concludes a simple polymeric drug depot, releasing the antibiotic over the critical period post-implantation and up to four weeks. The proof of concept was made using both in-vitro and in-vivo experiment, performs adequate drug release profile and even overcoming bacteria challenged implants [3].

Methods: Poly(hydroxyethyl-methacrylate) (pHEMA) hydrogel was used as a drug depot, containing Norfloxacin antibiotics as a drug model [4]. The sustained drug-release was achieved using subsequent surface modification of the pHEMA. The hydroxyl groups were reacted with octadecylisocyanate, forming hydrophobic mono-layer coating. The surface coating was optimized to allow sustained release over a period of four weeks. The device was examined in-vitro for the detection of the antibiotic release patterns using spectrophotometry. The antibiotic function of the device was then further examined in-vitro using a silicone biofilm model. In-vivo feasibility was investigated using rabbits model. The control group of rabbits underwent standard cataract surgery with intraocular lens (IOL) implant and post-operative topical antibiotic and steroid. The experimental group received the polymeric device inserted on the standard three-piece IOL at the time of surgery and received only topical steroids post-operatively. In order to examine the antibiotic effectiveness in-vivo, the experimental group was also challenged with Staphylococcus epidermidis bacteremia in concentration as high as 10^7/ml in 30μl bolus. In-vivo antibiotics levels were sampled from the anterior chamber for up to 30 days and the infection was tracked visually and ex-vivo. Clinical outcomes of both groups were also evaluated.

Results and Discussion: Our in-vitro data demonstrate that the pattern of antibiotic release can be achieved by optimization of the surface coating. The in-vivo results demonstrated sustained sufficient antibiotic concentration (above the minimum inhibitory concentration (MIC) for most common bacteria related to endophthalmitis) for more than four weeks. Minimum toxicity was observed in-vivo. Both groups of animals recovered from surgery without evidence of infection.

Conclusions: The initial findings of the polymeric drug delivery device demonstrate the feasibility of delivering sufficient antibiotic in the anterior chamber for the critical post-operative period in a rabbit model. The device is simple to produce and may help alleviate the potential post-surgical infections.

References